Unexplained weight loss (UWL), defined as a loss of more than 5% of body weight within six to twelve months without a clear cause, is a common yet challenging clinical scenario. It can be a harbinger of serious underlying diseases, making its evaluation crucial in clinical practice.
UWL can be attributed to a myriad of conditions. These include malignancies, gastrointestinal disorders, endocrine diseases, infections, and psychiatric illnesses. In some cases, medications or aging may also cause weight loss. However, in approximately 15-25% of cases, the cause remains elusive even after extensive investigation.
A systematic and comprehensive approach to evaluating UWL is essential. A detailed history and physical examination are the cornerstones of diagnosis, often providing clues to the underlying cause. Laboratory tests, imaging studies, and endoscopic procedures may be required based on clinical suspicion. A watchful waiting approach may be appropriate in some patients, given that the cause of UWL may become apparent over time.
While imaging is not routinely recommended in the evaluation of UWL, it may be beneficial in certain scenarios. For instance, CT scans can be useful in detecting occult malignancies or abdominal pathologies. However, the use of imaging should be guided by the patient's history and physical examination findings.
Management of UWL is primarily directed towards treating the underlying cause, if identified. In cases where no cause is found, symptomatic treatment and regular follow-up are essential. Nutritional support may be required in patients with significant weight loss.
In conclusion, evaluating UWL necessitates a comprehensive and systematic approach, with a focus on history taking, physical examination, and judicious use of investigations. While challenging, a meticulous approach can often yield the underlying cause, enabling targeted treatment and improving patient outcomes.
1.
Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars
2.
The Growing Role of AI in Cancer Treatment
3.
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
4.
Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.
5.
Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training
1.
Drug Exposure in Tumor Microenvironments: Mechanisms, Clinical Implications, and Emerging Strategies
2.
Proteoform Networks in Blood Disorders: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
3.
Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025
4.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
5.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
How Multidisciplinary Teams Support Modern Cancer Care
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation